STRM.BIO

Cambridge, Massachusetts, United States · Biotechnology, Health Care, Therapeutics · 14 employees

STRM.BIO is a biotechnology company developing a non-viral, cell-derived delivery modality that enables safe, targeted, and scalable in vivo delivery of genetic medicines. Its megakaryocyte-derived vesicle (MV) platform is designed to address the limitations of traditional viral and synthetic delivery systems, unlocking new therapeutic opportunities across gene editing, RNA therapeutics, and immun

See plans & pricing → Track STRM.BIO’s funding, hiring, and signals — with verified contacts — on Fundz.